LEGN
Legend Biotech Corporation
A biopharmaceutical company that engineers patients' own immune cells into CAR-T therapies to fight blood cancer, best known for CARVYKTI, a treatment for multiple myeloma developed and sold with Johnson & Johnson's Janssen. It began in 2014 in Nanjing, China, as a spinout from GenScript and was first called the "Legend Project." For its first two years the tiny team reportedly worked in a space the size of a freight elevator, and the name "Legend" was chosen to signal global ambition.
ADRUnderlying: LEGNCUSIP: 52490G102HealthcareUS1 holder
American Depositary Shares (ADS) - each ADS represents 2 ordinary shares
Total Value
$10.48M
Total Shares
362.8K
Net Share Change
-364.4K
Activity
1 selling
Investor
Value
Shares
Weight
Change
